Panelists discuss how breakthrough bleeding affects approximately 20% of users initially but improves over time and can be managed through patient education about expectations, nonsteroidal anti-inflammatory drugs (NSAIDs) for acute episodes, and adjustments to estrogen dose or progestin type when necessary.
Panelists discuss how providers can utilize resources like Postpartum Support International for training, certification, and referrals, while building community networks and making warm handoffs to ensure patients receive appropriate care without barriers.
Panelists discuss how shortened hormone-free intervals (24-4 and 24-2-2 regimens) prevent ovarian reactivation and endometrial proliferation that caused breakthrough bleeding with traditional 21/7 formulations, while addressing how amenorrhea can be viewed as either a desired therapeutic outcome or concerning adverse effect depending on patient preferences.
Panelists discuss how misconceptions about lower efficacy and increased drug interactions persist with low-dose estrogen pills, while adverse effects such as headaches and nausea are managed through anticipatory guidance and proper counseling without creating unnecessary anxiety.
New research reveals that pregnant women living in socioeconomically disadvantaged neighborhoods face a significantly higher risk of developing gestational diabetes.
An expert discusses how the ideal vasomotor symptom treatment would address both symptoms and bone loss simultaneously, making nonestrogen therapies with skeletal benefits like elinzanetant particularly attractive for patients.
An expert discusses how pooled clinical trial data shows fezolinetant does not cause weight gain or body mass index changes, though specific weight and muscle mass studies are not yet published
Discover practical strategies for clinicians to assist pregnant patients impacted by care restrictions, including travel guidance, emotional support, and resource access.
A new study reveals that restrictive post-Dobbs abortion laws are preventing doctors from providing necessary care, resulting in avoidable harm to pregnant patients.
Panelists discuss how new FDA-approved treatments like zuranolone offer rapid onset options for postpartum depression, while monitoring effectiveness requires regular follow-up, rescreening, symptom assessment, and addressing global factors like sleep support and breastfeeding pressures.
Panelists discuss how treatment barriers include limited prescriptive access and long wait times, while successful treatment plans require assessing severity levels, maternal functioning, support systems, and incorporating follow-up care with appropriate interventions based on the patient’s specific needs.
Panelists discuss how the drospirenone/estetrol (E4) pill with 14.2 mg of estrogen provides effective contraception with a long half-life progestin that accommodates typical user behavior, while explaining that milligram vs microgram dosing reflects different estrogen metabolism rather than higher exposure.
Panelists discuss how the norethindrone acetate/ethinyl estradiol pill with 10 mcg of estrogen became the best-selling branded pill in the US due to its effective 24/2/2 formulation that minimizes bleeding issues through reduced placebo days and low-dose estrogen support.
By analyzing electronic health records, researchers such as Marina Sirota, PhD, and Umair Khan have uncovered hundreds of conditions linked to endometriosis.
An expert discusses how fezolinetant appears to have neutral effects on bone density and bone health based on current 52-week study data in postmenopausal women.
An expert discusses how the OASIS-3 subanalysis provides intriguing evidence for potential long-term bone health benefits from elinzanetant alongside vasomotor symptom treatment, warranting further research.
A new study using advanced pregnancy preference measures reveals that heavy alcohol use significantly increases the risk of unintended pregnancy, highlighting the need for personalized contraceptive support.
Panelists discuss how to manage positive screens through resources like Postpartum Support International, state psychiatric consultation lines, combination therapy approaches, and addressing patient concerns about medication through evidence-based conversations and gradual implementation.
Panelists discuss how to overcome patient reluctance to discuss postpartum depression through normalization, early conversations during pregnancy, comprehensive screening integration, and addressing stigma by comparing mental health treatment with other medical conditions.
Panelists discuss how estrogen dosing selection depends on individual patient factors, including cycle control needs, noncontraceptive goals, estrogen sensitivity, age considerations for bone health, and patient comfort with hormone levels, with most providers using lower doses primarily to address estrogen-related adverse effects.
Panelists discuss how ideal candidates for combined hormonal contraceptives are those medically cleared for estrogen use who prefer predictable monthly periods, while progestin-only methods are recommended for patients with estrogen contraindications such as elevated body mass index (BMI) combined with older age or hypertension with migraines.
An expert discusses how elinzanetant demonstrated favorable body composition changes including weight loss, decreased fat mass index, and increased lean mass index in postmenopausal women.
An expert discusses how elinzanetant showed less bone mineral density decrease, reduced bone turnover markers, and increased total body bone density compared to placebo, suggesting beneficial skeletal effects.
Panelists discuss how effective screening goes beyond formal tools like the Edinburgh Postnatal Depression Scale to include genuine patient connection, direct questioning about emotional well-being, and clinical observation, while emphasizing the important role pediatricians can play in identifying maternal mental health concerns during frequent baby visits.
Panelists discuss how reproductive psychiatry is an evolving subspecialty that requires collaboration between obstetricians, primary care providers, and psychiatrists, with clear guidelines for when to refer patients (such as those with bipolar history, psychosis, or treatment resistance) while building capacity for basic screening and treatment in obstetric settings.
Panelists discuss how progestins have evolved from early norethindrone compounds through more potent but androgenic levonorgestrel to newer options such as drospirenone and dienogest, each offering different benefits for cycle control, noncontraceptive effects, and adverse effect profiles.
Panelists discuss how most combined hormonal contraceptives contain ethinyl estradiol for its long half-life and cycle control benefits, while newer natural estrogens such as estradiol and estetrol offer different tissue selectivity and potentially reduced liver impacts.
A new FDA-submitted self-collection HPV test aims to improve cervical cancer screening access for underserved women by offering a convenient, noninvasive at-home option.
An expert discusses how the OASIS-3 trial was designed as a 52-week placebo-controlled study in postmenopausal women with moderate to severe vasomotor symptoms, including experimental bone health end points.
An expert discusses how neurokinin receptor antagonists like fezolinetant (NK3) and elinzanetant (NK1/NK3) work in the hypothalamus to reduce vasomotor symptoms, with elinzanetant showing promising skeletal benefits.
